HER2-Targeted Therapy—From Pathophysiology to Clinical Manifestation: A Narrative Review
Trastuzumab is the primary treatment for all stages of HER2-overexpressing breast cancer in patients. Though discovered over 20 years ago, trastuzumab-induced cardiotoxicity (TIC) remains a research topic in cardio-oncology. This review explores the pathophysiological basis of TIC and its clinical m...
Main Authors: | Svetoslava Elefterova Slavcheva, Atanas Angelov |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Journal of Cardiovascular Development and Disease |
Subjects: | |
Online Access: | https://www.mdpi.com/2308-3425/10/12/489 |
Similar Items
-
Insights into monkeypox pathophysiology, global prevalence, clinical manifestation and treatments
by: Liyan Niu, et al.
Published: (2023-03-01) -
Levodopa-Induced Dyskinesias in Parkinson’s Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions
by: Lazzaro di Biase, et al.
Published: (2023-06-01) -
Pathophysiology, clinical manifestations and current management of IL-1 mediated monogenic systemic autoinflammatory diseases, a literature review
by: Yandie Li, et al.
Published: (2022-10-01) -
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01) -
Development of cardiac risk prediction model in patients with HER-2 positive breast cancer on trastuzumab therapy
by: Prince Otchere, et al.
Published: (2023-05-01)